Journal of Clinical Oncology | 2019

Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Abstract


425Background: Avelumab, a human anti‒PD-L1 IgG1 antibody, is approved for the treatment of metastatic urothelial cancer (mUC) progressing after platinum chemotherapy in the US, Canada, and Israel....

Volume 37
Pages 425-425
DOI 10.1200/JCO.2019.37.7_SUPPL.425
Language English
Journal Journal of Clinical Oncology

Full Text